Citing an increase in the number of outstanding shares due to option exercises and vesting of restricted share units, BeiGene (NASDAQ:BGNE) and cancer collaboration partner Amgen (NASDAQ:AMGN) have agreed to increase the number of shares allowable to the latter in order for it to maintain its 20.5% stake.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.